VivoSeq
Oncology

Platinum-Resistant Ovarian Cancer

11

Pipeline Programs↗

6

Active Trials↗

6

Companies Involved↗

Platinum-resistant Ovarian Cancer is an emerging landscape with 11 programs across 6 companies. The most active players are Stemline Therapeutics, Inc., Genmab, Teva. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Stemline Therapeutics, Inc.

1 program

Phase 1Genmab logo

Genmab

1 program

Phase 3Teva logo

Teva

1 program

Phase 3M

Meitheal

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

8 of 10 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody110%Gene therapy110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 86% of 14 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Not yet recruiting1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Recruiting·GGenelux Corporation·Phase 3·NCT05281471·186 enrolled
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
Recruiting·SStemline Therapeutics, Inc.·Phase 1·NCT07226427·100 enrolled
A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Recruiting·IImmunityBio, Inc.·Phase 2·NCT06710288·20 enrolled
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer
Recruiting·RRoswell Park Cancer Institute·Phase 1·NCT07489287·18 enrolled
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Active, not recruiting·Genmab logoGenmab·Phase 3·NCT06619236·530 enrolled
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Not yet recruiting·Genmab logoGenmab·Phase 3·NCT07604766·82 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)